U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
Meta Expands AI Training With Employee Activity Tracking Tools 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
BOTHELL, Wash., March 28, 2017 -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that it will webcast its presentation at the upcoming 16th Annual Needham Healthcare Conference at 5:00 p.m. ET (2:00 p.m. PT) on Tuesday, April 4, 2017 in New York, NY. The presentation will feature a business overview and update by Randall C. Schatzman, Ph.D., president and chief executive officer.
A live audio webcast can be accessed on the Events & Presentations page of the Investors section of Alder’s website at http://www.alderbio.com, or by following the link below in your web browser. An archived replay of the webcast will be available on Alder’s website for 30 days after the live event concludes.
Link: http://wsw.com/webcast/needham80/aldr
About Alder BioPharmaceuticals, Inc.
Alder BioPharmaceuticals, Inc., is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder's lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention. Eptinezumab is a monoclonal antibody that inhibits calcitonin gene-related peptide (CGRP), a protein that is active in mediating the initiation of migraine. Alder is additionally evaluating ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine. Clazakizumab, Alder's third program, is a monoclonal antibody candidate that inhibits interleukin-6 and is licensed to Vitaeris, Inc. For more information, please visit http://www.alderbio.com.
Media Contacts: David Schull or Victoria Meissner Russo Partners, LLC (212) 845-4271 (646) 942-5627 [email protected] [email protected] Investor Relations Contact: David Walsey Alder Biopharmaceuticals (425) 408-8032 [email protected]
